Literature DB >> 10921964

Outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a Parisian hospital.

F Guerin1, A Buu-Hoï, J L Mainardi, G Kac, N Colardelle, S Vaupré, L Gutmann, I Podglajen.   

Abstract

Epidemiological relationships were investigated between 40 methicillin-resistant Staphylococcus aureus (MRSA) strains with decreased glycopeptide susceptibility isolated from November 1998 to March 1999 from 39 patients (17 infected and 22 colonized patients) in nine wards of the Broussais Hospital, Paris, France. Reduced glycopeptide susceptibility was readily detected on brain heart infusion (BHI) agar containing 6 microg of teicoplanin per ml and on gradient plates, but not by the standard disk diffusion method. The MICs of vancomycin and teicoplanin, determined on BHI agar, were 4 and 8 to 32 microg/ml, respectively (standard antibiotic dilution), and 4 to 8 and 8 to 32 microg/ml, respectively (E-test). All strains were resistant to macrolides, aminoglycosides, tetracycline, rifampin, sulfonamides, and pefloxacin, showed reduced susceptibility to fusidic acid and fosfomycin, and were susceptible to trimethoprim and chloramphenicol. Pulsed-field gel electrophoresis and lysotyping revealed that a multidrug-resistant MRSA clone with decreased susceptibility to glycopeptides has been discretely endemic since at least 1996 in our institution, where it was responsible for an outbreak in November and December 1998.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921964      PMCID: PMC87166     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals.

Authors:  O Chesneau; A Morvan; N E Solh
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

2.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

Authors:  M C Ploy; C Grélaud; C Martin; L de Lumley; F Denis
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

3.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

4.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

5.  Interim guidelines for prevention and control of Staphylococcal infection associated with reduced susceptibility to vancomycin.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-07-11       Impact factor: 17.586

6.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

7.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

Authors:  J Ariza; M Pujol; J Cabo; C Peña; N Fernández; J Liñares; J Ayats; F Gudiol
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

9.  Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; N J Dorman; S A Lerner
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

10.  Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

Authors:  J L Mainardi; D M Shlaes; R V Goering; J H Shlaes; J F Acar; F W Goldstein
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

View more
  20 in total

1.  First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin.

Authors:  J W Decousser; P Pina; J C Ghnassia; J P Bedos; P Y Allouch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-08       Impact factor: 3.267

2.  Clonal diversity among streptogramin A-resistant Staphylococcus aureus isolates collected in French hospitals.

Authors:  Julien Haroche; Anne Morvan; Marilyne Davi; Jeanine Allignet; François Bimet; Névine El Solh
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

3.  Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France.

Authors:  X Bertrand; D Hocquet; M Thouverez; P Plésiat; D Talon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-12       Impact factor: 3.267

4.  Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.

Authors:  N Aritaka; H Hanaki; L Cui; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Linezolid compared with vancomycin for the prevention of methicillin-resistant Staphylococcus aureus or Staphylococcus epidermidis vascular graft infection in rats: A randomized, controlled, experimental study.

Authors:  Suzan Sacar; Mustafa Sacar; Ilknur Kaleli; Semra Toprak; Nural Cevahir; Zafer Teke; Ali Asan; Barbaros Sahin; Ahmet Baltalarli; Huseyin Turgut
Journal:  Curr Ther Res Clin Exp       Date:  2007-01

6.  Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides.

Authors:  G Werner; C Cuny; F J Schmitz; W Witte
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

7.  DNA macroarray for identification and typing of Staphylococcus aureus isolates.

Authors:  Salim Trad; Jeanine Allignet; Lionel Frangeul; Marilyne Davi; Massimo Vergassola; Elisabeth Couve; Anne Morvan; Amel Kechrid; Carmen Buchrieser; Philippe Glaser; Névine El-Solh
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

8.  Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin.

Authors:  Andrea Reipert; Kerstin Ehlert; Thomas Kast; Gabriele Bierbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in liver transplant recipients.

Authors:  Frédéric Bert; Juliette Clarissou; François Durand; Didier Delefosse; Chantal Chauvet; Patricia Lefebvre; Nicole Lambert; Catherine Branger
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 10.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.